ID4 gene is a member of the inhibitor of DNA-binding (ID) family, which inhibits DNA binding of basic helixloop-helix transcription factors. Certain human primary breast cancers reportedly have low or no expression of ID4 protein, but its role in carcinogenesis and cancer progression is unknown. To determine its possible role, we examined epigenetic inactivation of ID4 gene by promoter hypermethylation in human breast cell lines and T1 breast cancer tissues. Methylation status of ID4 promoter CpG island was assessed by methylation-specific PCR (MSP); ID4 mRNA level was assessed by quantitative real-time RT-PCR. Of eight cell lines, two were fully methylated, four were partially methylated, and two were not methylated. ID4 mRNA level was suppressed in fully methylated cell lines. ID4 hypermethylation was observed in 16 of 24 (67%) node-positive and seven of 36 (19%) node-negative T1 primary breast cancers matched by patient age and tumor diameter. It was a significant risk factor for nodal metastasis (OR 13.1, P ¼ 0.0004). ID4 mRNA level was suppressed in hypermethylated cancer specimens (P ¼ 0.014). ID4 may play an important suppressive role in tumor progression, and its silencing by hypermethylation may increase the risk of regional lymph node metastasis.
Introduction
The presence of axillary lymph node metastases is the most significant prognostic factor for patients with breast cancer (Fisher et al., 1993; Fitzgibbons et al., 2000) . For patients with early breast cancers, the ability to predict nodal metastasis could alleviate the need for axillary staging. The rate of nodal metastasis in T1 (p2.0 cm) breast cancers is reportedly from 18 to 31% (Carter et al., 1989; Holland et al., 1996; Barth et al., 1997) . There are several known risk factors of lymph node metastasis for invasive breast cancer to date. For nodal metastasis of T1 breast cancer, lymphovascular invasion, tumor size, histologic grade, histologic type, and estrogen receptor (ER) status are the major risk factors of pathological findings (Brenin et al., 2001) . We hypothesized that additional information about genetic alteration of cancer cells could be helpful for a prediction of nodal metastasis, and aimed to find new genetic markers of nodal metastasis. As advanced primary cancers have more lymphovascular invasion than early stage cancers, which directly causes metastasis and may mask the impacts of the genetic alterations, we considered that early cancers are more suitable for a study of assaying a new genetic marker that influence on regional lymph node metastasis. In addition, because genetic abnormalities are accumulated during cancer progression, we considered that early cancers would have simple correlations between genetic alterations and biological behavior.
Methylation of cytosines in CpG islands in the promoter region affects promoter activity and can downregulate gene transcription (Jones, 1999) . Since promoter hypermethylation is as significant as genetic deletions or mutations in cancer cells (Jones, 1996; Esteller and Herman, 2002; Herman and Baylin, 2003) , hypermethylation of key regulatory genes can play a significant role in transformation and biological behavior of invasive breast cancers. Progression of transformed cells requires inactivation of genes that regulate growth, and suppress dedifferentiation, invasion, and metastasis.
Transcription factors containing a basic helix-loophelix (bHLH) motif regulate the expression of certain tissue-specific genes (Pagliuca et al., 1995) and have important roles in cell differentiation and embryonic development. DNA-binding activity of the bHLH proteins is dependent on formation of homo-and/or heterodimers. Inhibitor of DNA-binding (ID) proteins, which are distinct members of the HLH protein family, contain the HLH-dimerization domain but lack the DNA-binding basic domain. Consequently, ID proteins form heterodimers with bHLH proteins and dominantly inhibit their binding to DNA and transcription, and modulate various key developmental processes (Massari and Murre, 2000) . Four human ID proteins have been identified to date. These proteins play critical roles in early embryonic development (Jen et al., 1996; Jen et al., 1997; Kee and Bronner-Fraser, 2001) , and are also involved in angiogenesis, lymphocyte development, cell cycle control, and cellular senescence (Benezra et al., 2001; Rivera and Murre, 2001; Zebedee and Hara, 2001) . Certain ID proteins might also be involved in neoplastic processes. Advanced breast cancers reportedly express ID1 (Lin et al., 2000; Singh et al., 2002) , and ID1 expression is associated with poor clinical outcome of patients with node-negative breast cancer (Schoppmann et al., 2003) . By contrast, expression of ID2 is low in invasive breast cancer and correlates with noninvasive phenotype (Itahana et al., 2003) . Expression of ID3 or ID4 in breast cancer has not been well studied.
Recently, it was reported that ID4 promoter is hypermethylated in 30% of primary gastric cancers, and ID4 expression is downregulated in most gastric cancer cell lines by hypermethylation of the promoter region (Chan et al., 2003) . In addition, we found that ID4 hypermethylation in 53% of sporadic primary colorectal cancers correlated with unfavorable prognosis (Umetani et al., 2004b) . In breast cancer, animal studies have demonstrated that ID4 regulates mammary epithelial cell growth and differentiation, and overexpression of this protein in rat mammary gland carcinomas correlates with proliferation, invasiveness, and tumor weight (Shan et al., 2003) . However, certain human primary breast cancers reportedly have low or no expression of ID4 protein by immunohistochemistry (IHC) (Welcsh et al., 2002) , suggesting downregulation of the ID4 gene. We hypothesized that ID4 may have a putative tumor suppressive role in early stages of breast cancer progression, and epigenetic inactivation of ID4 gene by promoter hypermethylation might favor regional lymph node metastasis. To examine this hypothesis, we assessed the relation between methylation status of ID4 promoter region and mRNA transcription level in breast cell lines and the correlation between ID4 hypermethylation and regional lymph node metastasis of T1 primary breast cancers.
Results

Cell line analysis
We initially assessed established breast cell lines to determine and optimize the methylation-specific PCR (MSP) assay for ID4 promoter region (Figure 1 ). Representative MSP results of ID4 promoter region in breast cancer cell lines are shown in Figure 2a in combination with those in breast cancer specimens in Figure 2b . Among the eight breast cell lines studied, two cell lines (T-47D and HBL-100) were fully methylated showing only methylated-specific peaks (methylation index (MI) ¼ 1.0), and four cell lines (MCF-7, BT20, BT549, and BR2) were partially methylated showing both methylated-specific and unmethylated-specific peaks (MI ¼ 0.55, 0.55, 0.53, and Figure 3 ). This observation indicated that ID4 mRNA transcription was inactivated by homozygous hypermethylation of promoter region.
Analysis of clinical specimens
To determine the clinical contribution of ID4 hypermethylation to tumor aggressiveness, we compared the methylation status of ID4 gene promoter region in primary tumors from patients with and without nodal metastasis. Case (node-positive, N ( þ )) and control (node-negative, N (À)) groups were matched by patient age and tumor size. Age at tumor resection (mean7s.e.m., years) was 56.072. Univariate logistic regression analysis for lymph node metastasis with ID4 methylation status and clinicopathological risk factors identified ID4 methylation status as a significant (OR 8.29, CI: 2.65-28.9; P ¼ 0.0005) risk factor (Table 1) . Lymphovascular invasion and HER2/neu values tended to correlate with nodal metastasis (P ¼ 0.067 and 0.097, respectively). No relation was found between the primary tumor's ID4 methylation status and its histologic grade (well/ moderate/poor) or type (invasive ductal/invasive lobular), ER status, DNA ploidy, S phase, or Ki-67 values. For multivariate logistic regression analysis, we selected covariates by forward stepwise selection with an entering cutoff P-value of 0.25 from ID4 methylation status and the above-described risk factors. Accordingly, ID4 methylation status, lymphovascular invasion, and HER2/Neu value were selected and incorporated into the regression model, and ID4 methylation status had significance (OR 13.1, CI: 3.50-61.8; P ¼ 0.0004) and HER2/neu had borderline significance (P ¼ 0.053) for lymph node metastasis (Table 2) .
To determine whether the ID4 mRNA level in clinical cancer specimens was suppressed by promoter hypermethylation, we assessed 10 specimens from hypermethylated cancers (MI range: 0.27-1.0, median: 0.44) and 10 specimens from unmethylated cancers (MI ¼ 0.0). Relative ID4 mRNA level was significantly lower in hypermethylated cancers (range: 0.0016-0.099, median: 0.018) than that in unmethylated cancers (range: 0.0045-1.31, median: 0.080) (P ¼ 0.014, Wilcoxon's rank sum test) ( Figure 6 ).
Discussion
It is very important to find risk factors of nodal metastasis especially in early stage primary breast cancers, because precise prediction of potential metastatic ability of the tumor could help the appropriate decision making of treatment. We considered that molecular markers for nodal metastasis might be more valuable than the conventional pathological risk factors (Brenin et al., 2001) , because the genetic changes can (Fisher et al., 1984; Fitzgibbons et al., 2000) , and background aberrant hypermethylation increases with age (Toyota and Issa, 1999) . We defined nodal metastasis based on staining with H&E as the gold standard in this study. We did not use special stains such as cytokeratin IHC because of the possibility of the detection of transported benign epithelial cells lacking metastatic potential (Carter et al., 2000; Moore et al., 2004) . Since ID4 is a dominant inhibitor of transcription factors and might be a key controlling factor for cell differentiation, we hypothesized that epigenetic regulation of ID4 gene might affect progression of breast cancer. The relation between ID4 promoter hypermethylation and mRNA transcription was initially determined in breast cell lines. ID4 mRNA transcription was inactivated in the fully methylated two breast cell lines. Same inactivation was also observed in colorectal cancer cell lines. Fully hypermethylated cell lines supposedly have homozygous methylation or monozygous methylation plus allelic loss at the ID4 locus. These findings support the hypothesis that ID4 gene can be inactivated by promoter hypermethylation. Previously, the restoration by the demethylating agent 5-aza-cytidine treatment had been demonstrated in gastric (Chan et al., 2003) and colorectal (Umetani et al., 2004b) cell lines as a confirmation of the inactivating mechanism. The two breast cell lines (T47D and HBL-100) that are fully hypermethylated are known to be less invasive, and these results seemed to be inconsistent with the hypothesis that the epigenetic inactivation of ID4 contributes to the aggressiveness of the cancer cells. However, because the characteristics of cell lines are determined by many kinds of genetic or epigenetic alteration, it is difficult to relate directly the cell characteristics to single gene expression. Further investigation for ID4 gene function in the breast cancer cells is mandatory as a future study.
Methylation status of cancer specimens was analysed without knowledge of clinicopathological status, including nodal metastasis. Methylation was objectively determined according to the intensity ratio of methylated-specific and unmethylated-specific peaks quantified by automated capillary array electrophoresis (CAE) system. Since MSP can detect a very small percentage of methylated DNA in abundant unmethylated DNA (Herman et al., 1996) , the MSP results would be positive even if only a small part of the microdissected tumor cells was hypermethylated. Frequency of aberrant hypermethylation of N (À) cancer specimens was lower than that of N ( þ ) cancer specimens, which suggested that ID4 gene inactivation might have enhanced the aggressiveness and risk of nodal metastasis. Furthermore, we demonstrated that hypermethylated breast primary cancer specimens have significantly lower mRNA level of ID4, indicating that ID4 transcription was similarly inactivated by promoter hypermethylation in clinical breast cancer specimens as the cell lines. However, the difference of mRNA level between the two groups was not prominent, suggesting that the entire cells in the hypermethylated tumors are not uniformly inactivated. Based on the hypothesis that primary breast cancers are genetically or epigenetically heterogeneous and metastasis occurs due to aggressive malignant clones, finding such aggressive clones among the other dominant clones within a tumor lesion with a sensitive genetic marker is clinically useful. If the ID4 suppression is an important mechanism for metastasis, detecting clones with ID4 suppression by quantifying the mRNA level is less sensitive. Therefore, we consider that detecting hypermethylated clones by highly sensitive methods such as MSP has greater potential for clinical utility than quantifying mRNA level.
Normal breast specimens showed approximately equivalent base line aberrant hypermethylation level as N (À) cancer specimens. As the normal tissue was obtained from adjacent normal mammary glands of cancer specimens, there was a possibility that occult cancer cells might be contaminated. There was another possibility that ID4 hypermethylation in premalignant mammary gland might be related to the carcinogenesis.
ID4 has been shown to be a regulator of BRCA1 expression (Beger et al., 2001) , and a negative coregulation of ID4 and BRCA1 was reported in breast cancer cell lines (Welcsh et al., 2002) . However, in primary breast cancers, ID4 expression was observed to be positively correlated with BRCA1 expression (Welcsh et al., 2002) . Epigenetic inactivation of ID4 gene may disrupt the ID4-BRCA1 regulatory loop. ID4 was reportedly overexpressed in rat mammary gland carcinomas and positively correlates with proliferation, invasiveness, and tumor weight (Shan et al., 2003) . Our results were contradictory to this animal study. Since ID4 can indirectly suppress many kinds of gene expression via downregulating bHLH transcription factors, the mechanism of ID4 function will be complicated. Further functional studies will elucidate the mechanisms of contribution of this gene to breast cancer development and/or progression.
In conclusion, this is the first report of ID4 promoter hypermethylation in breast cancer and its effect on lymph node metastasis. Hypermethylation of the promoter region appears to be a frequent phenomenon in human breast cancer and downregulates transcription of ID4 gene in breast cell lines and breast cancer tissues, and may increase the risk of lymph node metastasis. It is suggested that ID4 is a potential tumor suppressive gene that may play an important role in aggressiveness of tumor behavior. ID4 hypermethylation might prove useful as a genetic marker to predict early metastasis. Further investigation is needed to reveal the mechanisms by which ID4 inactivation contributes to tumor aggressiveness and promotes metastasis. 
Materials and methods
Cell lines
Six established breast cancer cell lines (MCF-7, T-47D, BT-20, BT-549, 734B, and MDA-MB-231), and an immortalized breast epithelial cell line HBL-100 from American Type Culture Collection (ATCC) (Manassas, VA, USA), and one breast cancer cell line (BR2) established in JWCI were analysed in this study. Additionally, three established colorectal cancer cell lines SW480, DLD1, and LOVO from ATCC were also analysed. Genomic DNA was extracted from cells as previously described (Spugnardi et al., 2003) . Total RNA was extracted using TRI Reagent (Molecular Research Center, Inc., Cincinnati, OH, USA), according to the manufacturer's protocol. Quality and quantity of extracted DNA and total RNA were measured by UV absorption spectrophotometry.
Tissue specimens and clinicopathology
All specimens were from formalin-fixed, paraffin-embedded archived tissues (PEAT) of female patients who underwent segmental or total mastectomy with sentinel lymph node biopsy and/or axillary lymph node dissection for T1 invasive breast cancer between 1996 and 2001 at Saint John's Health Center, Santa Monica. Lymph node metastasis was diagnosed with conventional H&E staining. Case-control methodology was adopted to reduce variations associated with tumor size and patient age. The N ( þ ) group consisted of 24 patients with axillary lymph node metastasis; the N (À) group consisted of 36 patients without lymph node metastasis, who were selected by matched-sampling to achieve the equivalent distribution of tumor size and age with the N ( þ ) group. The H&E-confirmed normal mammary gland tissues were obtained from the same sections of 11 cancer specimens. Tumors were classified and staged according to the guidelines set by the American Joint Committee on Cancer (AJCC). All patients in this study were consented according to the guidelines set forth by Saint John's Health Center and JWCI human subjects Institutional Review Board (IRB) committee.
Two 5-mm and one 10-mm sections were cut with a microtome from the PEAT blocks under sterile conditions as previously described (Umetani et al., 2004b) . One 5-mm section for each tumor was stained with H&E after deparaffinization as references of microdissection. For DNA methylation analysis, the tumor or normal tissues were precisely microdissected under a microscope from one 5-mm section as previously described (Umetani et al., 2004b) and subsequently digested with 50 ml of proteinase K containing lysis buffer. To compare the mRNA transcription level between hypermethylated cancers and unmethylated cancers, 10 specimens of each groups were selected and the tumor tissues were precisely microdissected under a microscope from one 10-mm section for each specimen as previously described (Umetani et al., 2004a) and subsequently mRNA was extracted with RNAwiz RNA Isolation Kit (Ambion, Austin, TX, USA) following the manufacturer's protocol.
Detection of hypermethylation
The methylation status of ID4 gene promoter region was evaluated by MSP, the specificity of which had been previously established by sodium bisulfite modification (SBM) sequencing (Umetani et al., 2004b) .
SBM was applied on extracted genomic DNA of tissue specimens and cell lines for MSP (Spugnardi et al., 2003) . Methylation status of ID4 promoter region was analysed by MSP as previously described (Umetani et al., 2004b) . The MSP primer sets were highly specific for detection of the methylation status of ID4 promoter (Figure 1 ). Forward primers for MSP covered the TATA box, E-box, and three CpG sites in the ID4 minimal promoter region (À48 to þ 32) (Umetani et al., 2004b) . The methylation-specific primer set was as follows: forward, 5 0 -D4-TTTTATAAATATAGTTGCGC GGC-3 0 ; reverse, 5 0 -GAAACTCCGACTAAACCCGAT-3 0 . The unmethylation-specific primer set was as follows: forward, 5 0 -D3-TTTTATAAATATAGTTGTGTGGTGG-3 0 ; reverse, 5 0 -TCAAAACTCCAACTAAACCCAAT-3 0 . Accuracy and reproducibility of these MSP primer sets had been confirmed by sodium bisulfite sequencing on peripheral blood leukocytes and hypermethylated cancer cell lines using primer sets as previously described (Chan et al., 2003) . PCR amplification was performed in a 10-ml reaction volume with 1 ml template for 40 cycles of 30 s at 941C, 30 s at 581C, and 30 s at 721C, followed by a 7-min final extension at 721C. Mg 2 þ concentration was 1.5 mM for methylated-specific and 2.5 mM for unmethylated-specific primer sets. Primer concentration was 0.1 mM for methylated-specific and 0.4 mM for unmethylatedspecific primer sets. PCR products were detected and analysed by CEQ 8000XL CAE system (Beckman Coulter, Inc., Fullerton, CA, USA) using CEQ 8000 software version 6.0 (Beckman Coulter) as previously described (Hoon et al., 2004) . Methylation status of each specimen was determined by MI, which was calculated from the fluorescent signal intensities of methylated (M) and unmethylated (U) PCR products by following formula: MI ¼ M/(M þ U). The range of MI was from 0.0 in completely unmethylated template DNA to 1.0 in completely methylated template DNA. MI was measured twice for each specimen; values larger than 0.1 corresponded to hypermethylation.
Analysis of mRNA transcription level
Reverse-transcriptase reactions were performed on 1.0 mg of extracted total RNA using Moloney murine leukemia virus reverse-transcriptase (Promega, Madison, WI, USA) with oligo-dT primers, as previously described (Takeuchi et al., 2003) . For clinical specimens, random primers were additionally used. QRT assay was performed on the iCycler iQ RealTime thermocycler detection system (Bio-Rad Laboratories, Hercules, CA, USA), as previously described (Takeuchi et al., 2003) . For each PCR, the reaction mixture consisted of cDNA template synthesized by reverse-transcription from 250 ng of total RNA, 0.5 mM of forward primer (5 0 -CGCTCACTGCG CTCAACAC-3 0 ), 0.5 mM of reverse primer (5 0 -TCAGGC GGCCGCACACCT-3 0 ), and 0.6 mM of fluorescence resonance energy transfer (FRET) probe (5 0 -FAM-CATTCTGTGCC GCTGAGCCG-BHQ-3 0 ). PCR amplification was performed in a 20-ml reaction volume 3 mM of Mg 2 þ for 45 cycles: 30 s at 941C, 30 s at 581C, and 30 s at 721C. Absolute copy numbers were determined by a standard curve with serial dilutions (10 8 -10 0 copies) of DNA containing ID4 cDNA sequence. Analysis without templates was performed as a negative control in each study. PCR products were electrophoresed on 2% agarose gels to confirm product size and absence of nonspecific bands. The transcription level of the house-keeping gene GAPDH was measured by qRT as an internal reference with a standard curve to determine the integrity of template RNA for all specimens. The relative mRNA level of ID4 was calculated as: absolute copy number of ID4/absolute copy number of GAPDH in 250 ng of total RNA (Takeuchi et al., 2003) . Median values of triplicated quantification were used for analysis. 
